Lipid A-modified Escherichia coli can produce porcine parvovirus virus-like particles with high immunogenicity and minimal endotoxin activity

Microb Cell Fact. 2024 Aug 8;23(1):222. doi: 10.1186/s12934-024-02497-9.

Abstract

Background: A cost-effective Escherichia coli expression system has gained popularity for producing virus-like particle (VLP) vaccines. However, the challenge lies in balancing the endotoxin residue and removal costs, as residual endotoxins can cause inflammatory reactions in the body.

Results: In this study, porcine parvovirus virus-like particles (PPV-VLPs) were successfully assembled from Decreased Endotoxic BL21 (BL21-DeE), and the effect of structural changes in the lipid A of BL21 on endotoxin activity, immunogenicity, and safety was investigated. The lipopolysaccharide purified from BL21-DeE produced lower IL-6 and TNF-α than that from wild-type BL21 (BL21-W) in both RAW264.7 cells and BALB/c mice. Additionally, mice immunized with PPV-VLP derived form BL21-DeE (BL21-DeE-VLP) showed significantly lower production of inflammatory factors and a smaller increase in body temperature within 3 h than those immunized with VLP from BL21-W (BL21-W-VLP) and endotoxin-removed VLP (ReE-VLP). Moreover, mice in the BL21-DeE-VLP immunized group had similar levels of serum antibodies as those in the BL21-W-VLP group but significantly higher levels than those in the ReE-VLP group. Furthermore, the liver, lungs, and kidneys showed no pathological damage compared with the BL21-W-VLP group.

Conclusion: Overall, this study proposes a method for producing VLP with high immunogenicity and minimal endotoxin activity without chemical or physical endotoxin removal methods. This method could address the issue of endotoxin residues in the VLP and provide production benefits.

Keywords: Escherichia coli; Lipid A; Minimal endotoxin activity; Porcine parvovirus; Virus-like particle.

MeSH terms

  • Animals
  • Endotoxins* / immunology
  • Escherichia coli* / genetics
  • Escherichia coli* / metabolism
  • Female
  • Interleukin-6 / immunology
  • Lipid A* / analogs & derivatives
  • Lipid A* / immunology
  • Lipopolysaccharides / immunology
  • Mice
  • Mice, Inbred BALB C*
  • Parvovirus, Porcine* / genetics
  • Parvovirus, Porcine* / immunology
  • RAW 264.7 Cells
  • Swine
  • Tumor Necrosis Factor-alpha / metabolism
  • Vaccines, Virus-Like Particle* / immunology

Substances

  • Vaccines, Virus-Like Particle
  • Endotoxins
  • Lipid A
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Lipopolysaccharides